n. any one of a group of gastrointestinal hormones that cause a decrease in blood glucose levels by stimulating an enhanced release of insulin from the pancreatic beta cells after eating. Thus they help to regulate the rise in blood glucose levels after eating and they have some additional actions that can enhance satiety – through effects on the brain and through gastrointestinal effects, such as delayed gastric emptying. Incretin-based drugs mimic the effects of the incretin *glucagon-like peptide-1 (GLP-1). They include *GLP-1 receptor agonists and *DPP-IV inhibitors.
a group of drugs used in the treatment of type 2 diabetes. They mimic the actions of *glucagon-like peptide-1 in regulating the rise in blood glucose levels after eating and they also enhance satiety (see incretin). As these drugs respond to a falling blood glucose level there is a reduced tendency to *hypoglycaemia compared with *sulphonylurea drugs and insulin therapy itself. They are given by subcutaneous injection and three of them are licensed for use in the UK: exenatide (Byetta; twice daily dosing), liraglutide (Victoza; once daily dosing), and lixisenatide (Lyxumia; once daily dosing).... glp-1 receptor agonists
(GLP-1) a hormone – an *incretin – that is produced in the small intestine. GLP-1 has a half-life in the blood circulation of less than two minutes due to rapid breakdown by the enzyme dipeptidyl peptidase-IV (DPP-IV). It is a potent antihyperglycaemic hormone, stimulating the release of insulin from the pancreatic beta cells in response to a rising blood glucose level after eating. This glucose-sensitive action also allows the effect of GLP-1 on the beta cells to switch off when the blood glucose level comes down to the normal baseline between meals. Thus the *GLP-1 receptor agonist group of drugs, used in type 2 diabetes, can restrict the rise in blood glucose level after meals but have a low risk of causing subsequent *hypoglycaemia.... glucagon-like peptide-1
Health Encyclopedia